Quantification of ceramide species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry

Analytical Biochemistry

Volumn 401, Issue 1, 2010, Pages 154-161

  Kasumov, Takhar ^a   Huang, Hazel ^a   Chung, Yoon Mi ^a   Zhang, Renliang ^a   McCullough, Arthur J ^a   Kirwan, John P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Ceramide; ESI MS MS; Insulin resistance; Lipidomics; Sphingolipid

Indexed keywords

CELL DEATH; COLUMN CHROMATOGRAPHY; ELECTROSPRAY IONIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; MUSCLE; PLASMA (HUMAN); RATS; SILICA; SILICA GEL;

CERAMIDE; ESI-MS/MS; INSULIN RESISTANCE; LIPIDOMICS; SPHINGOLIPIDS;

CERAMIDES;

CERAMIDE;

ACCURACY; ADULT; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; EXERCISE; HEART; HUMAN; LIQUID CHROMATOGRAPHY; LIVER; MALE; MUSCLE TISSUE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PRODUCT RECOVERY; QUANTITATIVE ANALYSIS; RAT; RELIABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

RATTUS;

EID: 77951091722     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.02.023     Document Type: Article

References (39)

1. Huwiler A., Kolter T., Pfeilschifter J., Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta 2000, 1485:63-99.
2. Clarke C.J., Snook C.F., Tani M., Matmati N., Marchesini N., Hannun Y.A. The extended family of neutral sphingomyelinases. Biochemistry 2006, 45:11247-11256.
3. Ohanian J., Ohanian V. Sphingolipids in mammalian cell signalling. Cell. Mol. Life Sci. 2001, 58:2053-2068.
4. Pewzner-Jung Y., Ben-Dor S., Futerman A.H. When do Lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J. Biol. Chem. 2006, 281:25001-25005.
5. Osawa Y., Uchinami H., Bielawski J., Schwabe R.F., Hannun Y.A., Brenner D.A. Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J. Biol. Chem. 2005, 280:27879-27887.
6. Seumois G., Fillet M., Gillet L., Faccinetto C., Desmet C., Fran{eth}cois C., Dewals B., Oury C., Vanderplasschen A., Lekeux P., Bureau F. De novo C16- and C24-ceramide generation contributes to spontaneous neutrophil apoptosis. J. Leukocyte Biol. 2007, 81:1477-1486.
7. Koybasi S., Senkal C.E., Sundararaj K., Spassieva S., Bielawski J., Osta W., Day T.A., Jiang J.C., Jazwinski S.M., Hannun Y.A., Obeid L.M., Ogretmen B. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J. Biol. Chem. 2004, 279:44311-44319.
8. Holland W.L., Summers S.A. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocrinol. Rev. 2008, 29:381-402.
9. Pickersgill L., Litherland G.J., Greenberg A.S., Walker M., Yeaman S.J. Key role for ceramides in mediating insulin resistance in human muscle cells. J. Biol. Chem. 2007, 282:12583-12589.
10. Samad F., Hester K.D., Yang G., Hannun Y.A., Bielawski J. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes 2006, 55:2579-2587.
11. Adams J.M., Pratipanawatr T., Berria R., Wang E., DeFronzo R.A., Sullards M.C., Mandarino L.J. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 2004, 53:25-31.
12. Kolak M., Westerbacka J., Velagapudi V.R., Weagsèater D., Yetukuri L., Makkonen J., Rissanen A., Heakkinen A.M., Lindell M., Bergholm R., Hamsten A., Eriksson P., Fisher R.M., Oresic M., Yki-Jearvinen H. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007, 56:1960-1968.
13. Haus J.M., Kashyap S.R., Kasumov T., Zhang R., Kelly K.R., Defronzo R.A., Kirwan J.P. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009, 58:337-343.
14. Alkhouri N., Dixon L.J., Feldstein A.E. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Exp. Rev. Gastroenterol. Hepatol. 2009, 3:445-451.
15. Preiss J.E., Loomis C.R., Bell R.M., Niedel J.E. Quantitative measurement of sn-1,2-diacylglycerols. Methods Enzymol. 1987, 141:294-300.
16. Gorska M., Dobrzyn A., Zendzian-Piotrowska M., Namiot Z. Concentration and composition of free ceramides in human plasma. Horm. Metab. Res. 2002, 34:466-468.
17. Dobrzyn A., Gorski J. Ceramides and sphingomyelins in skeletal muscles of the rat: content and composition-Effect of prolonged exercise. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E277-E285.
18. Yano M., Kishida E., Muneyuki Y., Masuzawa Y. Quantitative analysis of ceramide molecular species by high performance liquid chromatography. J. Lipid Res. 1998, 39:2091-2098.
19. Tserng K.Y., Griffin R. Quantitation and molecular species determination of diacylglycerols, phosphatidylcholines, ceramides, and sphingomyelins with gas chromatography. Anal. Biochem. 2003, 323:84-93.
20. Dobrzyn A., Knapp M., Gorski J. Effect of acute exercise and training on metabolism of ceramide in the heart muscle of the rat. Acta Phys. Scand. 2004, 181:313-319.
21. Blachnio-Zabielska A., Baranowski M., Zabielski P., Gorski J. Effect of exercise duration on the key pathways of ceramide metabolism in rat skeletal muscles. J. Cell. Biochem. 2008, 105:776-784.
22. Turinsky J., O'Sullivan D.M., Bayly B.P. 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J. Biol. Chem. 1990, 265:16880-16885.
23. Yamaguchi M., Miyashita Y., Kumagai Y., Kojo S. Change in liver and plasma ceramides during d-galactosamine-induced acute hepatic injury by LC-MS/MS. Bioorg. Med. Chem. Lett. 2004, 14:4061-4064.
24. Ichi I., Nakahara K., Fujii K., Iida C., Miyashita Y., Kojo S. Increase of ceramide in the liver and plasma after carbon tetrachloride intoxication in the rat. J. Nutr. Sci. Vitaminol. 2007, 53:53-56.
25. Schmelzer K., Fahy E., Subramaniam S., Dennis E.A. The lipid maps initiative in lipidomics. Methods Enzymol. 2007, 432:171-183.
26. Sullards M.C., Allegood J.C., Kelly S., Wang E., Haynes C.A., Park H., Chen Y., Merrill A.H. Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: " inside-out" sphingolipidomics. Methods Enzymol. 2007, 432:83-115.
27. Haynes T.A., Duerksen-Hughes P.J., Filippova M., Filippov V., Zhang K. C18 ceramide analysis in mammalian cells employing reversed-phase high-performance liquid chromatography tandem mass spectrometry. Anal. Biochem. 2008, 378:80-86.
28. Bligh E.A., Dyer W.J. A rapid and simple method for the determination of esterified fatty acids and for total fatty acids in blood. Can. J. Biochem. Physiol. 1959, 37:911-917.
29. Gu M., Kerwin J.L., Watts J.D., Aebersold R. Ceramide profiling of complex lipid mixtures by electrospray ionization mass spectrometry. Anal. Biochem. 1997, 244:347-356.
30. Liebisch G., Drobnik W., Reil M., Trèumbach B., Arnecke R., Olgemèoller B., Roscher A., Schmitz G. Quantitative measurement of different ceramide species from crude cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS/MS). J. Lipid Res. 1999, 40:1539-1546.
31. Bielawski J., Szulc Z.M., Hannun Y.A., Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006, 39:82-91.
32. Merrill A.H., Sullards M.C., Allegood J.C., Kelly S., Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 2005, 36:207-224.
33. Ichi I., Nakahara K., Miyashita Y., Hidaka A., Kutsukake S., Inoue K., Maruyama T., Miwa Y., Harada-Shiba M., Tsushima M., Kojo S. Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids 2006, 41:859-863.
34. Groener J.E., Poorthuis B.J., Kuiper S., Hollak C.E., Aerts J.M. Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim. Biophys. Acta 2008, 1781:72-78.
35. Baranowski M., Blachnio A., Zabielski P., Gorski J. Pioglitazone induces de novo ceramide synthesis in the rat heart. Prostaglandins Other Lipid Mediat. 2007, 83:99-111.
36. Mano N., Oda Y., Yamada K., Asakawa N., Katayama K. Simultaneous quantitative determination method for sphingolipid metabolites by liquid chromatography/ionspray ionization tandem mass spectrometry. Anal. Biochem. 1997, 244:291-300.
37. Tani M., Ito M., Igarashi Y. Ceramide/sphingosine/sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. Cell. Signal. 2007, 19:229-237.
38. Lochhead K.M., Zager R.A. Fluorinated anesthetic exposure " activates" the renal cortical sphingomyelinase cascade. Kidney Intl. 1998, 54:373-381.
39. Lightle S., Tosheva R., Lee A., Queen-Baker J., Boyanovsky B., Shedlofsky S., Nikolova-Karakashian M. Elevation of ceramide in serum lipoproteins during acute phase response in humans and mice: role of serine-palmitoyl transferase. Arch. Biochem. Biophys. 2003, 419:120-128.